Open-label, single-center, phase 1, drug-drug interaction study of rimegepant and ethinyl estradiol (EE)/norgestimate (NGM) in healthy females of childbearing potential or non-menopausal females with tubal ligation
Latest Information Update: 09 May 2023
At a glance
- Drugs Ethinylestradiol/norgestimate (Primary) ; Rimegepant (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- 09 May 2023 New trial record
- 04 May 2023 Results published in the Headache